Home › Trials › NCT07345247

Radiation segmentectomy with Y-90 resin microspheres for liver tumors

RAdiation SEgmentectomy With REsin Microspheres (RASEREM) Study

Observational Ankara University · NCT07345247

This will test whether injecting Y-90 resin microspheres into the tumor-bearing part of the liver is safe and can shrink tumors in adults with liver cancer.

Quick facts

Study typeObservational
Enrollment150 (estimated)
Ages18 Years and up
SexAll
SponsorAnkara University Academic / other
Drugs / interventionsRadiation
Locations20 sites (Adana and 19 other locations)
Trial IDNCT07345247 on ClinicalTrials.gov

What this trial studies

This is a multicenter prospective observational registry of adults with hepatocellular carcinoma or liver metastases treated with selective Y-90 resin microsphere infusion to the tumor-bearing hepatic segment. Teams will record administered dose, liver function, imaging responses, and adverse events at scheduled follow-up visits to determine safety and to describe dose thresholds linked to complete radiologic response. The main analysis will relate segmental radiation dose to rates of complete response, local control, and treatment-related toxicity. Data from participating centers in Adana, Turkey will be pooled to produce practical dose recommendations for resin microsphere segmentectomy.

Who should consider this trial

Good fit: Adults (≥18) with HCC or liver metastases who have one to three tumors confined to the same or neighboring liver segments, tumor size under 8 cm, Child–Pugh score below B9, and who can attend follow-up visits are ideal candidates.

Not a fit: Patients with macrovascular invasion, disease outside the liver, cholangiocarcinoma or mixed HCC‑cholangiocarcinoma, or those unable/unwilling to attend follow-up are unlikely to benefit from this protocol.

Why it matters

Potential benefit: If successful, the study could define safe and effective dose limits for Y-90 resin segmentectomy and help doctors use this treatment more confidently.

How similar studies have performed: Existing evidence using glass microspheres shows strong safety and efficacy for radiation segmentectomy and retrospective reports suggest resin microspheres can work at lower doses, but prospective multicenter data for resin devices are limited.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Patients aged ≥18 years
* Underwent RE as a RS intent (have single or \<3 tumors in same or neighboring 2 segments) for the treatment of HCC or metastatic tumor to liver.
* Presence of extrahepatic disease
* Tumor size less than 8 cm
* Child Pugh Score \<B9

Exclusion Criteria:

* Presence of macrovascular invasion,
* Presence of extrahepatic disease,
* Cholangiocarcinoma or mixed HCC-cholangiocarcinoma
* Not willing to attend follow-up visits.

Where this trial is running

Adana and 19 other locations

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Liver Cancer, AdultLiver CancerRadioembolization
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.